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Abstract  15 
 16 
G-protein-coupled receptor 40 (GPR40) is known to play a role in the regulation of fatty acids, 17 
insulin secretion and inflammation. However, the function of this receptor in human neutrophils, one 18 
of the first leukocytes to arrive at the site of infection, remains to be fully elucidated. In the present 19 
study, we demonstrate that GPR40 is upregulated on activated human neutrophils and investigated 20 
the functional effects upon treatment with a selective agonist; GW9508. Interestingly, GPR40 21 
expression was up-regulated after neutrophil stimulation with platelet-activating factor (PAF, 10nM) 22 
or leukotriene B4 (LTB4, 10nM) suggesting potential regulatory roles for this receptor during 23 
inflammation. Indeed, GW9508 (1 and 10µM) increased neutrophil chemotaxis in response to the 24 
chemokine IL-8 (30ng/ml) and enhanced phagocytosis of E. coli by approximately 50% when tested 25 
at 0.1 and 1µM. These results were translated in vivo whereby administration of GW9508 (10mg/kg, 26 
i.p.) during E. coli infections resulted in elevated peritoneal leukocyte infiltration with a higher 27 
phagocytic capacity. Importantly, GW9508 administration also modulated the lipid mediator profile, 28 
with increased levels of the pro-resolving mediators resolvin D3 and lipoxins. In conclusion, GPR40 29 
is expressed by activated neutrophils and plays an important host protective role to aid clearance of 30 
bacterial infections. 31 
 32 
1. Introduction 33 
 34 
GPR40 (also known as free fatty acid receptor 1, FFAR1), is a member of the G-protein coupled 35 
receptor (GPCR) family. Many agonists have been discovered to bind and activate GPR40 such as 36 
medium- and long-chain fatty acids, including omega-3 docosahexaenoic acid (DHA)  (Briscoe et al., 37 
2003) as well as 17,18-epoxyeicosatetraenoic acid (17,18-EpETE), a bioactive lipid mediator derived 38 
from eicosapentaenoic acid (EPA) (Nagatake et al., 2018). GPR40 is highly expressed in pancreatic 39 
beta cells, where it is involved in the regulation of insulin secretion (Itoh et al., 2003). Indeed, due to 40 
its pivotal role in insulin regulation a number of synthetic agonists have been developed such as 41 
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Fasiglifam (TAK-875) and GW9508, which exert beneficial effects in diabetes (Burant et al., 42 
2012;Ou et al., 2013). Importantly, there is evidence that GPR40 also plays a role in regulating the 43 
inflammatory response, for example by counteracting inflammasome activation and limiting contact 44 
hypersensitivity (Yan et al., 2013;Nagatake et al., 2018). However, the functional role of GPR40 in 45 
the context of the innate immune response to infection and whether it plays a role in the resolution of 46 
inflammation remains to be fully elucidated. 47 
 48 
In the present study, we demonstrate that GPR40 expression is up-regulated on human neutrophils 49 
under inflammatory settings. Using in vitro assays, we demonstrated that GW9508-stimulation 50 
induces calcium mobilization, increases neutrophil chemotaxis towards IL-8 and enhances bacterial 51 
phagocytosis. In an acute model of E. coli infection, GW9508 improved clearance of E. coli by 52 
peritoneal leukocytes and reprogrammed the lipid mediator expression towards a more pro-resolution 53 
profile. Our work identified a previously unknown role of GPR40 in enhancing neutrophil responses, 54 
which is important for maintaining host defence against pathogens.  55 
 56 
2. Materials and Methods 57 
 58 
Blood collection: Volunteers gave written consent in accordance with a Queen Mary Research Ethics 59 
Committee (QMREC 2014:61). Venous peripheral blood was collected from healthy volunteers into 60 
sodium citrate (3.2%), and neutrophils were isolated using dextran sedimentation followed by 61 
gradient centrifugation.  62 
 63 
Collection of exudated human neutrophils: A model of acute neurogenic inflammation was 64 
performed to collect activated human neutrophils from the oral cavity according to a protocol 65 
approved by the Queen Mary Research Ethics Committee (QMREC2010/17). Volunteers were asked 66 
to rinse the buccal cavity three times with 20ml of 0.9% saline for 30 seconds, followed by a 10% 67 
Tabascoâ solution (20ml for 30 seconds). The volunteers were nil by mouth for the following two 68 
hours, prior to rinsing the buccal cavity again three times with 20ml of 0.9% saline (Speight et al., 69 
2010). Mouthwash samples were collected, passed through a 70µm strainer and centrifuged at 300g 70 
for 10 mins at room temperature. Cells were washed with 50ml of DPBS-/-, passed through a 40µm 71 
strainer to remove epithelial cells and centrifuged at 300g for 10 mins at room temperature. The 72 
supernatant was discarded and the cells were gently re-suspended for further analysis.  73 
 74 
Flow cytometry: Neutrophils were stimulated with vehicle (0.1% ethanol), TNF-α (10ng/ml), IL-8 75 
(10ng/ml), PAF (10nM) or LTB4 (10nM) for 10 min at 37ºC prior to analysis of GPR40 expression. 76 
Cells were fixed and permeabilized according to manufacturer’s instructions (eBioscience), then 77 
incubated with anti-GPR40 (0.181µg/ml, clone EP4632; Abcam) for 30 mins on ice, washed 3 times 78 
and a goat anti-rabbit secondary antibody (AlexaFluor 488, Life Technologies) was added for 45 79 
mins on ice. GPR40 expression was recorded as MFI units in the FL1 channel of a BD FACSCalibur 80 
or in the B530/30 channel of a BD LSR Fortessa. 81 
 82 
ImageStream analysis: Cells were incubated with APC-anti-CD11b (clone ICRF44; eBioscience) 83 
and PE-Cy5-anti-CD62L (clone DREG56; eBioscience) for 45 min at 4o C in DPBS containing 84 
0.02% BSA. After staining, red blood cells were lysed using Whole Blood Lysing Reagent Kit, 85 
according to the manufacturer’s instructions. Staining was then assessed using ImageStream X MK2 86 
and analysis was performed using IDEAS® (Image Data Exploration and Analysis Software, Version 87 
6.0).  88 
 89 
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Intracellular calcium mobilization: Human neutrophils were incubated with 2 µM Fura 2-AM 90 
(Molecular Probes, Paisley, U.K.) in HBSS without Ca2+ (Sigma-Aldrich) at 37°C for 45 min in the 91 
dark then washed three times with HBSS. HBSS containing 0.185g/L CaCl2 was then added before 92 
stimulation with GW9508 (0 -10 µM) or Ionomycin (1 µM). Mobilization of intracellular calcium 93 
was measured for 70 s after treatment by recording the ratio of fluorescence emission at 510 nm after 94 
sequential excitation at 340 and 380 nm using the NOVOstar microplate reader (BMG LABTECH, 95 
Aylesbury, U.K.). The results are expressed as percentage of the positive control (ionomycin) or as 96 
delta of time zero. 97 
 98 
Chemotaxis assay: Human neutrophils were stimulated with GW9508 (0.1 -10µM) or vehicle for 10 99 
mins at 37°C. Chemotaxis was performed using 3-µm pore size ChemoTx™ 96 well plates (Neuro 100 
Probe Inc, Gaithersburg, USA) (Frevert et al., 1998) for 90 min. Briefly, migrated cells were 101 
collected from the bottom chamber and incubated with PrestoBlue® (Invitrogen Ltd. Paisley, UK) 102 
and compared with a standard curve constructed with known cell numbers. Plates were read after 4h 103 
in a fluorescence spectrophotometer at EX560-EM590 nm.  104 
 105 
Phagocytosis assay: Human neutrophils were stimulated with GW9508 (0.1 - 10µM) for 10 mins at 106 
37°C in RPMI containing 0.1% FBS. After treatment, BODIPY (576/589)-labelled E. coli (1mg/ml) 107 
was added for 30 mins at 37°C, 5% CO2 and then neutrophils were washed three times with cold 108 
DPBS to remove bacteria that had not been phagocytosed. Phagocytosis levels were determined 109 
using a fluorescence plate reader and are expressed as fluorescence intensity or as the percentage of 110 
the positive control.  111 
 112 
Apoptosis: Human neutrophils were stimulated with GW9508 (10µM) or vehicle and incubated at 113 
37oC in a 5% CO2 incubator. After 2, 8, 18 and 24 hours of incubation, neutrophils were loaded in 114 
cytospin chambers, fixed in methanol and stained with H&E. 200 cells per slide were counted with 115 
x100 objective. In another set of experiments, apoptosis was assessed by flow cytometry with the 116 
Dead Cell Apoptosis Kit according to manufacturer’s instructions. Briefly, after 18h incubation, 117 
neutrophils (1x105) were washed twice and resuspended in 1X binding buffer, followed by the 118 
addition of Annexin V FITC and PI for 15 mins at room temperature in the dark. Samples were 119 
analysed within 1 hour and AnxV binding and PI staining was recorded as MFI units in the B530/30 120 
and YG610/20 channels respectively, using a BD LSR Fortessa. 121 
 122 
Animals: Male C57BL/6 mice (8 weeks old) were procured from Charles River (Kent, UK). 123 
Experiments strictly adhered to UK Home Office regulations (Scientific Procedures Act, 1986) and 124 
Laboratory Animal Science Association (LASA) Guidelines. All animals were provided with 125 
standard laboratory diet and water ad libitum and kept on a 12h light/dark cycle. 126 
 127 
Peritonitis: E. coli (serotype O6:K2:H1) were cultured in LB broth and harvested at mid-log phase 128 
(OD600 ~0.5, 5×108CFU/ml) and washed in sterile saline before inoculation into the mouse 129 
peritoneum. Mice were given live E. coli (1x105) i.p. and treated with GW9508 (10mg/kg 100ul, i.p.) 130 
or vehicle 1h later. After 12 h, mice were euthanized and peritoneal exudates and blood were 131 
collected. Leukocyte infiltration to the peritoneum was assessed using Ly6G PE (clone 1A8, 132 
eBioscience) for neutrophils, Ly6C eFluor450 (clone HK1.4, eBioscience) for monocytes and F4/80 133 
BV650 (clone: BM8, eBioscience) for macrophages. Phagocytosis of E.coli was determined 134 
following cell permeabilization and staining with FITC-conjugated E.coli antibody (GeneTex). 135 
 136 
Targeted lipid mediator profiling: All samples for LC-MS-MS-based profiling were extracted 137 
using solid-phase extraction columns (Dalli et al., 2018). 3 ml of peritoneal exudate were placed in 138 
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ice-cold methanol containing deuterated internal standards, representing each region in the 139 
chromatographic analysis (500 pg each). Samples were kept at -20°C for 45 min to allow protein 140 
precipitation. Supernatants were subjected to solid phase extraction, methyl formate fraction 141 
collected, brought to dryness and suspended in phase (methanol/water, 1:1, vol/vol) for injection on a 142 
Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector, paired with a QTrap 5500 143 
(Sciex). An Agilent Poroshell 120 EC-C18 column (100 mm x 4.6 mm x 2.7 µm) was kept at 50°C 144 
and mediators eluted using a mobile phase consisting of methanolwater-acetic acid of 20:80:0.01 145 
(vol/vol/vol) that was ramped to 50:50:0.01 (vol/vol/vol) over 0.5 min and then to 80:20:0.01 146 
(vol/vol/vol) from 2 min to 11 min, maintained till 14.5 min and then rapidly ramped to 98:2:0.01 147 
(vol/vol/vol) for the next 0.1 min. This was subsequently maintained at 98:2:0.01 (vol/vol/vol) for 5.4 148 
min, and the flow rate was maintained at 0.5 ml/min. The QTrap 5500 was operated using a multiple 149 
reaction monitoring method. Each LM was identified using established criteria including matching 150 
retention time to synthetic and authentic materials and at least 6 diagnostic ions (Dalli et al., 2018). 151 
 152 
Statistical analysis: Results are presented as mean ± SEM. Differences between groups were 153 
assessed using GraphPad Prism 7 (GraphPad Software, La Jolla, USA) and 1-way ANOVA with post 154 
hoc Dunnett’s or Student’s t-test. The criterion for statistical significance was p < 0.05. Partial least 155 
squares-discrimination analysis (PLS-DA) and principal component analysis (PCA) (Janes, 2006) 156 
were performed using SIMCA 14.1 software 6 (Umetrics, Umea, Sweden) following mean centering 157 
and unit variance scaling of LM levels. PLS-DA is based on a linear multivariate model that 158 
identifies variables that contribute to class separation of observations (peritoneal exudates) on the 159 
basis of their variables (LM levels). During classification, observations were projected onto their 160 
respective class model. The score plot illustrates the systematic clusters among the observations 161 
(closer plots presenting higher similarity in the data matrix). Loading plot interpretation identified the 162 
variables with the best discriminatory power (Variable Importance in Projection greater than 1) that 163 
were associated with the distinct intervals and contributed to the tight clusters observed in the Score 164 
plot.  165 
 166 
3. Results 167 
 168 
GPR40 expression is upregulated on activated human neutrophils.  169 
We first assessed whether GPR40 was expressed by human neutrophils and whether it could be 170 
differentially modulated following cell activation. To mimic inflammatory settings, neutrophils were 171 
stimulated with TNF-α, IL-8, PAF or LTB4 for 10 mins and GPR40 levels were analysed by flow 172 
cytometry. GPR40 was moderately increased by TNF-α (10ng/ml) and IL-8 (10ng/ml) when 173 
compared to vehicle (0.1% ethanol) treated cells (Figure 1A). Whereas PAF (10nM) and LTB4 174 
(10nM) stimulation significantly increased GPR40 levels (Figure 1A). GPR40 expression was also 175 
visualized by imaging flow cytometry, which demonstrated localisation throughout the cell in resting 176 
neutrophils characterised by low CD11b and high L-selectin surface levels (Figure 1Error! 177 
Reference source not found.B).  178 
It is well known that neutrophil recruitment to the site of inflammation results in the activation of 179 
these adhesion molecules. The sensing of chemokines, and the physical contact with endothelial cells 180 
promotes a change in neutrophil phenotype, with substantial alterations in cellular composition, due 181 
to release of secretory vesicles and granules (Borregaard et al., 2007). Thus, a model of acute 182 
neurogenic inflammation was performed to collect activated human neutrophils from the oral cavity. 183 
As expected, neutrophils freshly isolated from whole blood exhibited basal expression levels of 184 
CD11b, whereas significantly higher levels were detected on extravasated neutrophils, promoted by 185 
tabasco mouth wash (Figure 1Error! Reference source not found.C). Conversely, blood neutrophils 186 
expressed high levels of L-selectin that was shed during recruitment (Figure 1Error! Reference 187 
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source not found.D). Interestingly, GPR40 expression was significantly higher on exudate 188 
neutrophils when compared to neutrophils isolated from peripheral blood of the same individual, 189 
further confirming that activated neutrophils express higher GPR40 levels (Figure 1Error! 190 
Reference source not found.E). 191 
 192 
Next, it was essential to demonstrate that GPR40 was functional on human neutrophils, thus 193 
GW9508, a selective GPR40 agonist, was tested. Previous studies investigating GPR40 signalling in 194 
pancreatic islet cells have eluded that this GPCR is coupled to the α subunit of the Gq family of G 195 
proteins, leading to PLC activation, hydrolysis of inositol lipids and increased intracellular calcium 196 
levels (Hardy et al., 2005). Therefore, we measured the intracellular calcium flux in human 197 
neutrophils treated with a concentration range (0.1-10µM) of GW9508, or ionomycin as a positive 198 
control. At all concentrations tested, GW9508 promoted an intracellular calcium flux that was 199 
significantly greater than the vehicle control (Figure 1F-G).  200 
 201 
GW9508 enhances neutrophil functionality.  202 
Since GPR40 was upregulated on activated neutrophils and GW9508 treatment induced intracellular 203 
signalling, we next investigated the functional significance of the GPR40-GW9508 axis on 204 
neutrophil reactivity. Thus, the effects of GW9508 on neutrophil chemotaxis in response to the 205 
chemokine IL-8 were assessed. Isolated human neutrophils were incubated with vehicle (0.1% 206 
ethanol) or pre-incubated with GW9508 (0.1, 1 and 10µM) for 10 min, and the migratory response to 207 
IL-8 tested. Incubation of neutrophils with GW9508 enhanced the chemotactic response compared 208 
with vehicle alone. This effect was concentration-dependent, with the highest concentration of 10µM 209 
evoking an 80% increase in cell migration compared with IL-8 alone (Figure 2A). 210 
 211 
One of the major functions of neutrophils is to safely and efficiently clear bacteria and cellular debris, 212 
to help bring the tissue back to homeostasis, a key step in the resolution of inflammation. Thus, we 213 
next investigated whether GW9508 could alter the phagocytic ability of neutrophils. Phagocytosis 214 
was determined after incubation for 90min with fluorescently labelled Escherichia coli. Neutrophils 215 
treated with GW9508 had an increased phagocytic capacity, as determined by the amount of 216 
intracellular E. coli. Indeed, 0.1µM GW9508 increased neutrophil phagocytosis by approximately 217 
50% when compared to vehicle.  The optimal concentration of GW9508 was 1µM, leading to 218 
enhanced phagocytosis of 60% over vehicle treatment (Figure 2B).  219 
 220 
After neutrophils have killed pathogens and cleared debris it is essential that they undergo apoptosis, 221 
a process of controlled cell death necessary for their safe removal from an inflammatory site. Cell 222 
death by necrosis, on the other hand can cause tissue damage by release of harmful substances such 223 
as reactive oxygen species and proteases following rupture of the cell membrane. Therefore, the 224 
effects of GW9508 on neutrophil cell death were determined by measuring annexin V binding and 225 
propidium iodide (PI) staining after culturing overnight in RPMI containing 0.1% FBS (18h). 226 
Surprisingly, GW9508 decreased the number of apoptotic cells (Figure 2C) and enhanced neutrophil 227 
survival (Figure 2D). Importantly, GW9508 did not induce cellular necrosis as determined by the 228 
percentage of AnxV-PI+ cells (Figure 2E), with representative flow cytometry plots shown in Figure 229 
2F. We therefore performed a full time-course of neutrophil apoptosis to determine whether GW9508 230 
would prolong the lifespan of neutrophils (Figure 2G). GW9508 prevented neutrophil apoptosis as 231 
early as 2h after stimulation, an effect that was observed up to 18h after treatment (Figure 2G). Yet 232 
almost 100% of neutrophils were apoptotic by 24h, with or without treatment, suggesting that the 233 
effects of GW9508 are temporal. GW9508 treatment had no significant impact on the clearance of 234 
apoptotic PMN via the process of efferocytosis (data not shown).    235 
    236 
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GW9508 enhances leukocyte recruitment and bacterial clearance in vivo.    237 
Next, we questioned whether the chemotactic and phagocytic properties of GW9508 visualized in 238 
vitro would remain in vivo. Mice were inoculated with live E.coli (105) i.p. to induce peritonitis, 239 
followed by GW9508 (10mg/kg/mouse) or vehicle control (0.1%PBS) 1h later, and mice were 240 
sacrificed after 12h at peak neutrophil infiltration (Chiang et al., 2012). Peritoneal exudates of 241 
GW9508 treated mice contained an increased number of total leukocytes (Figure 3A), more 242 
specifically neutrophils and monocytes, compared to vehicle-treated mice (Figure 3B, C). 243 
Macrophage numbers were not significantly altered at this time point (Figure 3D). Importantly, 244 
GW9508-treatment led to increased numbers of E.coli positive neutrophils and monocytes (Figure 245 
3E, F) compared to vehicle-treated mice, indicating enhanced containment and clearance of bacteria.   246 
 247 
GW9508 stimulates pro-resolving lipid mediators during peritonitis. 248 
Given the host protective actions of GW9508 during E.coli infection, we next determined whether 249 
this response was associated with a pro-resolving signature by assessing the lipid mediator profile of 250 
the peritoneal exudates. Lipid mediators (LM) were identified and quantified by using liquid 251 
chromatography-tandem mass spectrometry-based LM profiling. The identity of lipid mediators was 252 
ascertained in accordance with published criteria, that included matching retention times to authentic 253 
or synthetic standards and identification of at least 6 diagnostic ions in the tandem mass spectrometry 254 
(MS-MS) fragmentation spectrum (Dalli et al., 2018). In these inflammatory exudates we identified 255 
mediators from all four essential fatty acid metabolomes, including D-series resolvins and lipoxins 256 
(Supplementary Table 1). Of note, the concentrations of these mediators were within their described 257 
bioactive ranges (Dalli et al., 2015). Multivariate analysis of peritoneal exudate LM profiles, 258 
demonstrated two distinct clusters representing LM profiles obtained from vehicle- and GW9508-259 
treated mice (Figure 4A, B). GW9508 treatment was associated with significantly increased levels of 260 
RvD3 and AA-derived lipoxins (Figure 4C, D). In addition, there was a 2-fold increase in the lipoxin 261 
pathway marker 5S,15S-diHETE (Figure 4E), a 3-fold increase in the levels of RvE1 and increased 262 
levels of RvE3 (Figure 4 F, G) in peritoneal exudates from GW9508-treated mice compared to 263 
vehicle control. 264 
 265 
4. Discussion 266 
 267 
Our data herein substantiates an important role for GPR40 in the host inflammatory response to 268 
curtail and contain bacterial infection. We made the novel observation that GPR40 is upregulated on 269 
human neutrophils upon activation with a variety of pro-inflammatory substances and following 270 
extravasation into the oral cavity in response to an inflammatory challenge. We utilised the well 271 
characterised GPR40 synthetic agonist GW9508 to elucidate the downstream actions of GPR40 272 
stimulation in human neutrophils. We found that GW9508 could enhance chemotaxis and 273 
temporarily prolong neutrophil lifespan, which we believe may be a mechanism to aid the timely 274 
clearance of bacteria. When tested in a self-limited infection model, GW9508 accelerated the 275 
resolution of E. coli infection by increasing leukocyte recruitment, phagocytic clearance of bacteria 276 
and stimulating certain pro-resolving lipid mediators.   277 
 278 
Neutrophils and their armamentarium contribute to initiation, development and resolution of the 279 
inflammatory response (Jones et al., 2016). Thus, control of when, where and how neutrophils act 280 
must be tightly regulated to maintain a healthy immune system. Neutrophil effector functions are 281 
regulated via a vast variety of receptors, some of which are contained in intracellular granules that 282 
can be rapidly mobilised to the cell surface upon neutrophil activation (Borregaard et al., 2007). 283 
Indeed, the phenotype of extravasated neutrophils is known to be significantly modulated compared 284 
with those circulating within the vasculature (Kolaczkowska and Kubes, 2013). In the oral cavity, it 285 
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has been reported that neutrophils elicited following capsaicin challenge are primed to produce 286 
significantly more reactive oxygen species (ROS) than resident neutrophils prior to challenge or 287 
peripheral blood neutrophils from the same donor (Speight et al., 2010). We report here that 288 
neutrophils migrating into the oral cavity in response to capsaicin have an activated phenotype with 289 
high levels of CD11b, minimal L-selectin levels and significantly higher levels of GPR40. This 290 
finding corroborates our in vitro experiments whereby the pro-inflammatory lipid mediators PAF and 291 
LTB4 upregulated GPR40 expression on isolated peripheral blood neutrophils. It is worth noting that 292 
elevated levels of GPR40 are also detected on renal epithelial cells in models of kidney fibrosis 293 
including unilateral ureteral obstruction, ischemic injury, and adenine-induced nephropathy, where it 294 
is deemed protective (Gagnon et al., 2018), thus suggesting that this receptor may be upregulated 295 
within inflammatory settings to assist, we propose, in resolution and tissue-reparative mechanisms. 296 
Notably, other pro-resolving receptors such as ChemR23 and FPR2/ALX are elevated on the cell 297 
surface of PMN following activation with inflammogens such as TNF-a and IL-8 (Cash et al., 2013) 298 
(Norling et al., 2012) as well as recruitment to human blisters (Morris et al., 2010), further supporting 299 
the concept that pro-resolving receptors can be rapidly mobilised to the cell membrane to counter 300 
regulate inflammation. 301 
 302 
G-protein coupled receptors are promiscuous both in terms of agonist activation as well as interaction 303 
with binding partners (Inoue et al., 2019). It is well known that GPR40 can be activated by various 304 
medium and long chain free fatty acids, often producing opposing actions (Briscoe et al., 2003). In 305 
this work, we focused on the use of GW9508, a synthetic agonist proven to be beneficial in diabetes, 306 
to elucidate whether the GPR40 pathway would be protective in the context of bacterial infection. 307 
Rapid recruitment of neutrophils and efficient chemotaxis to sites of infection are essential preludes 308 
to neutrophil function and clearance of bacteria. Intriguingly, GW9508 treatment can induce IL-8 309 
release from bovine neutrophils (Mena et al., 2016). This chemokine is a powerful attractant for both 310 
neutrophils and monocytes and may explain why higher numbers of these leukocytes are recruited to 311 
the peritoneal cavity following GW9508 administration (Figure 3) in a feed-forward mechanism.  312 
 313 
Depending on the agonist and environmental conditions, GPR40 signalling can either induce or 314 
protect from cellular apoptosis. Similarly to our findings with human neutrophils (Figure 2), 315 
GW9508 attenuated apoptosis of human renal epithelial cells in an injury model. The mechanism 316 
behind these protective actions included inhibition of reactive oxygen species (ROS) generation, pro-317 
apoptotic proteins and nuclear factor-κB (NF-κB) activation (Ma et al., 2014). Further studies are 318 
required to elucidate the mechanism by which GW9508 delays the spontaneous apoptosis of human 319 
neutrophils. 320 
 321 
Bacterial peritonitis caused by Escherichia coli infection is a clinically important problem with a 322 
high mortality rate (Ross et al., 2018). If infection is not contained and eliminated by phagocytes it 323 
can rapidly progress leading to excessive inflammation, epithelial and endothelial barrier 324 
dysfunction, immune suppression and multiple-organ failure that can be deadly. Thus, timely 325 
clearance of bacteria is essential. Importantly, we found that administration of GW9508 could 326 
enhance phagocytic clearance of E.coli from the peritoneum. Interestingly, another GPR40 agonist 327 
has been documented to prevent bacterial dissemination by inhibiting epithelial barrier impairment 328 
induced by the periodontopathic bacterium Porphyromonas gingivalis. This endogenous agonist is a 329 
bioactive metabolite generated by probiotic microorganisms during the process of fatty acid 330 
metabolism known as 10-hydroxy-cis-12-octadecenoic acid (HYA), which signals via GPR40 on 331 
gingival epithelial cells to exert its beneficial actions (Yamada et al., 2018). We have previously 332 
reported that alpha-2-macroglobulin loaded microparticles enhance host responses to infection by 333 
promoting neutrophil recruitment and clearance of bacteria whilst stimulating pro-resolving pathways 334 
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(Dalli et al., 2014), thus promoting a swift resolution of bacterial sepsis. Using a human blister model 335 
to investigate inflammation-resolution, Morris et al., reported that two types of responders exist, 336 
those with immediate leukocyte accumulation followed by early resolution and those with delayed 337 
resolution. Timely resolution of cantharidin-induced skin blisters was due at least in part to 338 
endogenous levels of 15epi-LXA4 and its receptor ALX/FPR2 expression (Morris et al., 2010). We 339 
therefore deem the enhanced leukocyte recruitment observed with GW9508 treatment in E.coli 340 
peritonitis to be a protective response to prevent the unwanted spread of bacteria.  341 
 342 
One of the mechanisms by which the GPR40 agonist GW9508 aided bacterial clearance was via 343 
regulation of specific specialized pro-resolving lipid mediators. These mediators derived from 344 
omega-3 and omega-6 fatty acids are known to stimulate phagocyte functions to control bacterial 345 
infections and accelerate the host immune response to infection (Chiang et al., 2012) (Padovan and 346 
Norling, 2020). Whilst we found that specific lipid mediators were elevated in response to the 347 
GPR40 agonist: these were RvD3, lipoxins, RvE1 and RvE3 (Figure 4). Notably, RvD3, lipoxins and 348 
RvE1 are effective in enhancing the clearance of Escherichia coli infection (Norris et al., 2018), 349 
bacterial pneumonia (Sekheri et al., 2020), and resolution of UV-killed E.coli in human blisters 350 
(Motwani et al., 2018). Systematic analysis of pro-resolving lipid mediator profiles in septic patients 351 
with acute respiratory distress syndrome (ARDS) indicated that the amount of circulating 10S,17S-352 
diHDHA (PDX) at day 3 was a better predictor of ARDS development than the APACHE II score 353 
(Dalli et al., 2017), further supporting the role of SPM in regulating host responses during infections.  354 
 355 
Together, our study indicates receptor-mediated actions of GW9508, with direct regulation of 356 
neutrophil function to enhance clearance of E.coli. We propose that GPR40 activation could be 357 
beneficial in infection not only through regulation of neutrophil responses but also through exquisite 358 
regulation of lipid mediators. Whether these effects are restricted to GW9508 and agonists which 359 
may behave in a similar fashion remains to be elucidated. In any case, uncovering new therapeutics 360 
that aid in the timely resolution of infection is imperative to prevent bacterial dissemination that 361 
could lead to unwanted organ damage and life-threatening conditions, and GPR40 could be explored 362 
to enable this long-term objective. 363 
 364 
 365 
Figure legends 366 
 367 
Figure 1: GPR40 expression and agonist activation in human neutrophils.  368 
A) Neutrophils isolated from healthy volunteers were stimulated with vehicle (0.1% ethanol), TNF-α 369 
(10ng/ml), IL-8 (10ng/ml), PAF (10nM) or LTB4 (10nM) for 10 min at 37ºC, and GPR40 expression 370 
monitored by flow cytometry. Results are mean ± SEM, n=4 * p<0.05 and ** p<0.01 vs. vehicle 371 
control using one-way ANOVA, followed by Dunnett’s post-test. B) Representative images of 372 
GPR40 expression in unstimulated neutrophils (CD11blowCD62Lhi) by ImagestreamTX (60x). C-E) 373 
Neutrophils were isolated from the peripheral blood and from the buccal cavity after mouth wash 374 
with Tabasco™ from healthy individuals and expression of C) CD11b, D) L-selectin and E) GPR40 375 
was monitored by flow cytometry, representative histograms are shown inset. Results are mean ± 376 
SEM, n=4. * p<0.05, **p<0.01 compared to peripheral blood using a paired T-test. F-G) Isolated 377 
neutrophils were incubated with Fura 2-AM and treated with vehicle control, ionomycin (positive 378 
control) or GW9508 (0.1, 1 and 10µM), and calcium flux was monitored over time. G) Intracellular 379 
calcium flux expressed as a percentage of the maximal response induced by ionomycin. Results are 380 
expressed as mean ± SEM from four independent experiments. ** p <0.01 and *** p <0.001 381 
compared to vehicle (0.1% ethanol); 1-way ANOVA, followed by Bonferroni post-test. 382 
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Figure 2: GW9508 enhances human neutrophil survival and function. 384 
A) Human neutrophils were isolated from healthy volunteers and treated with GW9508 (0.1-10µM) 385 
or vehicle (0.1% ethanol) for 10min at 37oC and chemotaxis to IL-8 (30ng/ml, 1h) was assessed. 386 
Results are expressed as mean ± SEM from four independent experiments. B) GW9508 treated 387 
neutrophils were incubated with BODIPY-labelled E. coli (30 mins, 37°C) and phagocytosis was 388 
assessed by fluorescence. Results are expressed as percent increase above vehicle, mean ± SEM from 389 
five independent experiments. C) Human neutrophils were treated with GW9508 (10µM), and were 390 
cultured overnight to allow spontaneous apoptosis. After 18 hours, annexin V binding and PI staining 391 
was assessed by flow cytometry for quantification of C) apoptotic (AnxV+PI-) D) live (AnxV-PI-) and 392 
E) necrotic (AnxV-PI+) cells. Results are expressed as mean ± SEM from three independent 393 
experiments. *p<0.05 compared to Veh; Unpaired T-test. (H) A time-course of neutrophil apoptosis 394 
was performed by assessing nuclear condensation by light microscopy following H&E staining. 395 
Results are expressed as mean ± SEM from three independent experiments. **p<0.01 compared to 396 
Veh; 2-way ANOVA, followed by Bonferroni post-test.  397 
 398 
Figure 3: GW9508 increases leukocyte recruitment and bacterial clearance. Mice were 399 
administered GW9508 (10mg/kg/mouse) or vehicle (PBS) and 1h later inoculated with E. coli. (105 400 
i.p.). Peritoneal exudates were collected after 12h and A) total leukocyte recruitment, B) neutrophils, 401 
C) monocytes and D) macrophages were enumerated. Phagocytic clearance of E.coli was quantified 402 
by flow cytometry by assessing the number of positive E) neutrophils and F) monocytes. Results are 403 
expressed as mean ± SEM, n=6 mice per group. *p<0.05, **p<0.01 compared to vehicle using an 404 
unpaired t-test.  405 
 406 
Figure 4: GW9508 induces SPM production in E. coli infected mice 407 
Mice were administered GW9508 (10mg/kg/mouse) or vehicle (PBS) and 1h later inoculated with E. 408 
coli. (105 i.p.). Peritoneal exudates were collected after 12h and lipid mediators were identified and 409 
quantified by using liquid chromatography tandem mass spectrometry (LC-MS/MS) lipid mediator 410 
profiling and exudate lipid mediator concentrations were assessed using A,B) Partial least squares 411 
discriminant analysis A) 2-dimensional (2D) score plot of the distinct LM-SPM profiles identified in 412 
the different treatment groups, B) corresponding 2D loading plot. Grey ellipse in the score plots 413 
denotes 95% confidence regions. Green and blue ellipses represent LM with a variable in importance 414 
score ≥1; n=5-6 mice per group. (C) RvD3, D) AA-derived lipoxins, E) 5S,15S-diHETE, F) RvE1 415 
and G) RvE3 concentrations identified and quantified in vehicle and GW9508 treated mice. Results 416 
are expressed as pg/mL and indicate the mean ± SEM, n=5-6 mice per group, *p≤0.05 vs. vehicle 417 
using an unpaired t-test. 418 
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